Response to the Commentary “Significance of Patient Registries for Dermatological Disorder”  by Horn, Liz et al.
Response to the Commentary ‘‘Significance of Patient
Registries for Dermatological Disorder’’
Journal of Investigative Dermatology (2013) 133, 1361; doi:10.1038/jid.2012.469; published online 13 December 2012
TO THE EDITOR
We were pleased to see the commen-
tary ‘‘Significance of Patient Registries
for Dermatological Disorder’’ by Dr de
Souza and Ms Miller (2012). Registries
are vital for teasing out complexities
of dermatologic disorders, especially
rare dermatologic diseases. The authors
highlighted the need for patient re-
gistries, as well as some of the
challenges associated with them (e.g.,
inadequate standards, lack of adherence
to standards, funding challenges, and
so on). We appreciate the authors’
acknowledgment of advocacy-led
registries. Advocacy organizations are
playing an increased role in clinical
research, including involvement in
registries and biobanks (Terry et al.,
2007; Landy et al., 2012). Whereas
some foundation-led registries are
designed for advocacy, educational, or
fundraising purposes as noted by the
authors, many foundations have devel-
oped registries to further the natural
history and epidemiologic understanding
of specific conditions.
The Pseudoxanthoma Elasticum Inter-
national Registry (www.pxe.org) collects
donor-reported epidemiological data
and has a corresponding biobank of
DNA and tissue samples. The National
Psoriasis Foundation (www.psoriasis.
org) also has a US-focused registry and
biobank with corresponding DNA sam-
ples. (The psuedoxanthoma elasticum
and psoriasis registries were not
included in the selected patient regis-
tries in dermatologic disorders). These
organizations, together with the US
Hereditary Angioedema Association
(www.haea.org), are all members of
Genetic Alliance Registry & BioBank, a
cooperative model to share infrastruc-
ture and expertise across member
organizations (Terry et al., 2011). The
three registries mentioned above,
similar to many registries, are funded
by the advocacy organizations that
run them (the article erroneously lists
industry funding for the HAEA scientific
registry). In the commentary, the Cystic
Fibrosis (CF) Registry is identified as a
gold standard. It would be of benefit to
the readership to identify areas in which
each registry listed in the article matches
or exceeds the CF registry. For ex-
ample, the International Pachyonychia
Congenita Registry offers free genetic
testing to all participants, and serves
patients in 50þ countries in seven
languages (Irvine, 2012). Although this
is just one example, there are likely
numerous successes from the other
registries listed and those not included.
The current system of academic
research and rewards is fractured and
unable to facilitate true collaboration
and sharing. This is not sustainable,
and as a community we have the oppor-
tunity and the obligation to improve
the biomedical ecosystem. It is clear
that advocacy organizations, individual
advocates, and citizen scientists are
essential partners for transforming the
system. Advocacy organizations are vital
partners for registries and biobanks, as
they are poised to develop communities
of trust and leverage scarce resources.
They understand the unmet research
needs of the community, can facilitate
collaboration between diverse stake-
holders, and are appropriate and
dedicated stewards of data and samples.
We encourage providers, researchers,
industry, and advocacy organizations to
work together to make these resources as
strong as they can be. We also thank the
authors for reminding the scientific com-
munity how important patient registries
are for dermatologic disorders.
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